

16C
PATENT**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE****In re Application of:**Donald L. Morton,
Rishab K. Gupta and
David M. Euhus

Group Art Unit: 1642

Examiner: M. Davis

Atty. Dkt. No.: CADL:002/SLH

Serial No.: 07/431,533

Filed: November 3, 1989

For: URINARY TUMOR ASSOCIATED
ANTIGEN, ANTIGENIC SUBUNITS
AND METHODS OF DETECTION**CERTIFICATE OF FACSIMILE TRANSMISSION**I hereby certify that this correspondence is being sent via facsimile (703) 308-4227
to Examiner Minh-Tam B. Davis with the U.S. Patent and Trademark Office,
Washington, D.C. 20231, on the date below:

February 14, 2001

Date

Steven J. Highlander

COMMUNICATION AND SUPPLEMENT TO SUPPLEMENTAL BRIEF UNDER
37 C.F.R. §1.193(b)(2)(ii)

BOX AF

Hon. Assistant Commissioner for Patents
Washington, DC 20231

Sir:

This is a supplemental reply to the Office Action mailed on June 21, 2000. On February 8, 2001, Examiner Davis placed a call to the undersigned requesting filing of the terminal disclaimer that was to be included with appellants' supplemental brief, filed on November 21, 2000. Upon review of the relevant files, the following facts have come to the undersigned's attention, and thus occasion the instant submission.

FACTS

1. The obviousness-type double-patenting rejection over the claims of U.S. Serial No. 08/462,570 was first advanced in the Office Action mailed on August 5, 1998. It has been maintained in each of the two subsequent Office Actions.

2. In an Office Action mailed on April 28, 1998, a similar obviousness-type double-patenting rejection was advanced against the '570 application over the claims of the present application. In a response filed on August 21, 1998, all the pending claims of the '570 were canceled and new claims added. It was argued therein that the new claims provided in the August 21st response, and contemporaneous amendments to the present application's claims, obviated that rejection.

3. On April 2, 1999, the examiner in the '570 application withdrew the obviousness-type double-patenting rejection and allowed the case without further amendment.


REMARKS

It is respectfully submitted that, *if the claims of the '570 application could be allowed over the claims of the present application, then there is no longer any conflict between these two cases.* In fact, the claims of the '570 application (now issued as U.S. Patent 5,993,828) are all drawn to *in vivo* stimulation of immune responses. All but one of the claims of the present application are drawn to compositions of matter, which clearly are patentably distinct from *in vivo* uses. Appellants hereby cancel the only other claim, claim 19, without prejudice or

disclaimer. As such, appellants respectfully request that the examiner reconsider and withdraw the obviousness-type double-patenting rejection now pending in the present application.

No fees are believed due in connection with this paper. However, should any fees be due, applicant authorizes the Assistant Commissioner to debit Fulbright & Jaworski Deposit Acct. No. 50-1212/10005391/SLH.

Respectfully submitted,



Steven L. Highlander
Reg. No. 37,642
Attorney for Applicant

FULBRIGHT & JAWORSKI
600 Congress, Suite 1900
Austin, Texas 78701
(512) 418-3000

Date: February 14, 2001

FULBRIGHT & JAWORSKI L.L.P.

A REGISTERED LIMITED LIABILITY PARTNERSHIP

800 CONGRESS AVENUE, SUITE 2400

AUSTIN, TEXAS 78701

TELEPHONE: 512/474-5201

FACSIMILE: 512/536-4598

FACSIMILE TRANSMISSION FROM: 512.536.4598

If any difficulties occur during transmission, 512.474.5201

DATE: February 14, 2001

FILE: CADL:002/10005391

DELIVER TO: Examiner: Minh-Tam B. Davis

COMPANY: United States Patent and Trademark Office

FAX NO.: (703) 308-4227

FROM: Steven L. Highlander

SENDER'S

PHONE: (512) 536-3184


RETURN ORIGINAL TO: Christopher Jackson

FLOOR: 20th

NO. OF PAGES TO FOLLOW: 3

ORIGINAL: WILL NOT FOLLOW

COMMENTS:

CERTIFICATE OF FACSIMILE TRANSMISSION 37 C.F.R. 1.8	
I hereby certify that this correspondence is being sent via facsimile (703) 308-4426 to Examiner Minh-Tam B. Davis with the U.S. Patent and Trademark Office, Washington, D.C. 20231, on the date below:	
February 14, 2001 Date	 Steven L. Highlander

CONFIDENTIALITY NOTICE: Unless otherwise indicated or obvious from the nature of the transmittal, the information contained in this facsimile message is attorney privileged and confidential information intended for the use of the individual or entity named above. If the reader of this message is not the intended recipient, or the employee or agent responsible to deliver it to the intended recipient, you are hereby notified that any dissemination, distribution or copying of this communication is strictly prohibited. If you have received this communication in error, please immediately notify the sender by telephone and return the original message to Fulbright & Jaworski L.L.P. at the above address via the U.S. Postal Service at our expense.

1664760.1